<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Circulating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell (CTC) counts are an established prognostic marker in metastatic prostate, breast and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and recent data suggest a similar role in late stage <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, due to sensitivity constraints in current enrichment-based CTC detection technologies, there are few published data about CTC prevalence rates and morphologic <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in early-stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>, or the correlation of CTCs with disease progression and their usability for clinical staging </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated CTC counts, <z:mp ids='MP_0000002'>morphology</z:mp> and aggregation in early stage, locally advanced and metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> patients by using a fluid-phase biopsy approach that identifies CTCs without relying on surface-receptor-based enrichment and presents them in sufficiently high definition (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) to satisfy diagnostic pathology image quality requirements </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-CTCs were analyzed in blood samples from 78 chemotherapy-naïve <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>73% of the total population had a positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-CTC count (&gt;0 CTC in 1 mL of blood) with a median of 4.4 HD-CTCs mL⁻¹ (range 0-515.6) and a mean of 44.7 (±95.2) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-CTCs mL⁻¹ </plain></SENT>
<SENT sid="5" pm="."><plain>No significant difference in the medians of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-CTC counts was detected between stage IV (n = 31, range 0-178.2), stage III (n = 34, range 0-515.6) and stages I/II (n = 13, range 0-442.3) </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-CTCs exhibited a uniformity in terms of molecular and physical characteristics such as fluorescent cytokeratin intensity, nuclear size, frequency of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and aggregate formation across the spectrum of staging </plain></SENT>
<SENT sid="7" pm="."><plain>Our results demonstrate that despite stringent morphologic inclusion criteria for the definition of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-CTCs, the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-CTC assay shows high sensitivity in the detection and characterization of both early- and late-stage <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> CTCs </plain></SENT>
<SENT sid="8" pm="."><plain>Extensive studies are warranted to investigate the prognostic value of CTC profiling in early-stage <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>This finding has implications for the design of extensive studies examining screening, therapy and surveillance in <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> patients </plain></SENT>
</text></document>